Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson files application to market generic Yasmin
Watson’s Drospirenone and Ethinyl Estradiol product is a generic version of Bayer’s Yasmin (drospirenone and ethinyl estradiol) tablet which is indicated for the prevention of pregnancy.
Watson’s Drospirenone and Ethinyl Estradiol product is a generic version of Bayer’s Yasmin (drospirenone and ethinyl estradiol) tablet which is indicated for the prevention of pregnancy.
As part of the approval for the manufacturing and marketing authorization of this drug, the Japanese regulatory authority made it obligatory for Pfizer Japan to conduct a post-marketing
The new drug application (NDA) provides for the safe and effective use of Carbaglu in the treatment of hyperammonaemia due to an autosomal genetic disorder resulting in the
In this proof-of-concept study in a non-human primate thrombolysis model, an appropriate dose of SMRX11 was administered as an intravenous bolus and successfully restored femoral arterial blood flow
Other new investors are Bessemer Venture Partners and Red Abbey Venture Partners. In connection with the financing, Ron Hunt, a managing director of New Leaf Venture Partners, and
Lpath’s Asonep Phase I trial is a dose-escalation study, with an initial dose of one milligram per kilogram of body weight (mg/kg) and subsequent doses of three, 10,
Under the agreement, Kinaxo will make its KinaTor technology available to Takeda researchers involved in drug discovery, preclinical research and clinical development. Kinaxo’s cellular target profiling utilizes proprietary
Loramyc has achieved its pre-specified two co-primary endpoints both in intent to treat (ITT) and per protocol (PP) populations. The primary end point was a complete resolution of
Ms Washington will report to John Milligan, the company’s COO. She will oversee company’s worldwide finance and investor relations functions and will serve as a member of the
The Phase I SBI-087 dose escalation clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of SBI-087 in patients with rheumatoid